New Drug Application News and Research

RSS
Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

Mylan announces U.S. launch of generic AXERT tablets

Mylan announces U.S. launch of generic AXERT tablets

Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison MediPharma begins sulfatinib Phase I trial in US

Braeburn, Camurus announce FDA Fast Track designation for CAM2038 to treat opioid addiction

Braeburn, Camurus announce FDA Fast Track designation for CAM2038 to treat opioid addiction

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Mylan announces U.S. launch of generic Fusilev for Injection

Mylan announces U.S. launch of generic Fusilev for Injection

Mast Therapeutics begins vepoloxamer Phase 2 study in patients with chronic heart failure

Mast Therapeutics begins vepoloxamer Phase 2 study in patients with chronic heart failure

Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Breakthrough research suggests that female sex hormone may save lives on the battlefield

Breakthrough research suggests that female sex hormone may save lives on the battlefield

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

AcelRx provides update on Zalviso (sufentanil sublingual tablet system)

AcelRx provides update on Zalviso (sufentanil sublingual tablet system)

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

First patients screened in Axovant's phase 3 study of RVT-101

First patients screened in Axovant's phase 3 study of RVT-101

AcelRx Pharmaceuticals initiates ARX-04 Phase 3 study in emergency room patients with acute pain

AcelRx Pharmaceuticals initiates ARX-04 Phase 3 study in emergency room patients with acute pain

FDA accepts Braeburn's resubmission of Probuphine NDA for review

FDA accepts Braeburn's resubmission of Probuphine NDA for review

Mylan releases generic version of Invega in the U.S.

Mylan releases generic version of Invega in the U.S.

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment